Adjuvant Therapy for Non-Small Cell Lung Cancer with Mediastinal Nodal Involvement

Thoracic Surgery Clinics

Volumn 18, Issue 4, 2008, Pages 423-435

  Sanborn, Rachel E ^a   Lally, Brian E ^b  

^a PROVIDENCE PORTLAND MEDICAL CENTER   (United States)

^b FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CISPLATIN; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; MELANOMA ANTIGEN 3; MITOMYCIN; NAVELBINE; PACLITAXEL; PLACEBO; UFT; VINDESINE;

ADD ON THERAPY; BRAIN METASTASIS; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DRUG FATALITY; DRUG MEGADOSE; DRUG WITHDRAWAL; ESOPHAGITIS; HUMAN; LUNG NON SMALL CELL CANCER; LUNG SURGERY; LYMPH NODE METASTASIS; MEDIASTINUM LYMPH NODE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; PATIENT COMPLIANCE; PNEUMONIA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION DOSE; REVIEW; SEPSIS; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; HUMANS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MEDIASTINUM; NEOPLASM STAGING; PNEUMONECTOMY;

EID: 53649099526     PISSN: 15474127     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thorsurg.2008.08.004     Document Type: Review

References (66)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2007. CA Cancer J Clin 57 (2007) 43-66
2. Kamangar F., Dores G.M., and Anderson W.F. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24 (2006) 2137-2150
3. Owonikoko T.K., Ragin C.C., Belani C.P., et al. Lung cancer in elderly patients: an analysis of the Surveillance, Epidemiology, and End Results database. J Clin Oncol 25 (2007) 5570-5577
4. Lee P.C., Port J.L., Korst R.J., et al. Risk factors for occult mediastinal metastases in clinical stage I non-small cell lung cancer. Ann Thorac Surg 84 (2007) 177-181
5. Douillard J.-Y., Rosell R., De Lena M., et al. Impact of postoperative radiation therapy on survival in patients with complete resection and stage I, II, or IIIA non-small-cell lung cancer treated with adjuvant chemotherapy: the Adjuvant Navelbine International Trialist Association (ANITA) randomized trial. Int J Radiat Oncol Biol Phys (2008) [PUBLISHED AHEAD OF PRINT]
6. Andre F., Grunenwald D., Pignon J.-P., et al. Survival of patients with resected N2 non-small-cell lung cancer: evidence for a subclassification and implications. J Clin Oncol 18 (2000) 2981-2989
7. Albain K.S., Swann R.S., Rusch V.R., et al. Phase III study of concurrent chemotherapy and radiotherapy vs CT/RT followed by surgical resection for stage IIIA (pN2) non-small cell lung cancer: outcomes update of North American Intergroup 0139 (RTOG 9309). [abstract]. Proc Am Soc Clin Oncol 23 (2005) 7014
8. Pieterman R.M., van Putten J.W.G., Meuzelaar J.J., et al. Preoperative staging of non-small-cell lung cancer with positron-emission tomography. N Engl J Med 343 (2000) 254-261
9. Hara M., Shiraki N., Itoh M., et al. A problem in diagnosing N3 disease using FDG-PET in patients with lung cancer: high false positive rate with visual assessment. Ann Nucl Med 18 (2004) 484-488
10. Shim S.S., Lee K.S., Kim B.-T., et al. Focal parenchymal lung lesions showing a potential of false-positive and false-negative interpretations on integrated PET/CT. Am J Roentgenol 186 (2006) 639-648
11. 18F]FDG-PET caused by non-neoplastic cellular elements after neoadjuvant chemoradiotherapy for non-small cell lung cancer. Jpn J Clin Oncol 35 (2005) 271-273
12. Silvestri G.A., Gould M.K., Margolis M.L., et al. Noninvasive staging of non-small cell lung cancer: ACCP evidenced-based clinical practice guidelines (2nd edition). Chest 132 (2007) 178S-201S
13. Tournoy K.G., De Ryck F., Vanwalleghem L.R., et al. Endoscopic ultrasound reduces surgical mediastinal staging in lung cancer: a randomized trial. Am J Respir Crit Care Med 177 (2008) 531-535
14. Wallace M.B., Pascual J.M.S., Raimondo M., et al. Minimally invasive endoscopic staging of suspected lung cancer. JAMA 299 (2008) 540-546
15. Non-Small-Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 311 (1995) 899-909
16. Arriagada R., Bergman B., Dunant A., et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 350 (2004) 351-360
17. Le Chevalier T., Dunant A., Arriagada R., et al. Long-term results of the International Adjuvant Lung Cancer Trial (IALT) evaluating adjuvant cisplatin-based chemotherapy in resected non-small cell lung cancer. [abstract]. Proc Am Soc Clin Oncol 26 (2008) 7507
18. Douillard J.-Y., Rosell R., De Lena M., et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol 7 (2006) 719-727
19. Scagliotti G.V., Fossati R., Torri V., et al. Adjuvant Lung Project Italy/European Organisation for Research Treatment of Cancer-Lung Cancer Cooperative Group Investigators. Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell lung cancer. J Natl Cancer Inst 95 (2003) 1453-1461
20. Waller D., Peake M.D., Stephens R.J., et al. Chemotherapy for patients with non-small cell lung cancer: the surgical setting of the Big Lung Trial. Eur J Cardiothorac Surg 26 (2004) 173-182
21. Pignon J.P., Tribodet H., Scagliotti G.V., et al. Lung Adjuvant Cisplatin Evaluation (LACE): a pooled analysis of five randomized clinical trials including 4,584 patients. [abstract]. Proc Am Soc Clin Oncol 24 (2006) 7008
22. The Study Group of Adjuvant Chemotherapy for Lung Cancer (Chubu, Japan). A randomized trial of postoperative adjuvant chemotherapy in non-small cell lung cancer (the second cooperative study). Eur J Surg Oncol 21 (1995) 69-77
23. Wada H., Hitomi S., Teramatsu T., et al. Adjuvant chemotherapy after complete resection in non-small-cell lung cancer. J Clin Oncol 14 (1996) 1048-1054
24. Nakagawa K., Tada H., Akashi A., et al. Randomised study of adjuvant chemotherapy for completely resected p-stage I-IIIA non-small cell lung cancer. Br J Cancer 95 (2006) 817-821
25. Tanaka F., Tsubota N., Namikawa S., et al. A randomized phase III trial of adjuvant chemotherapy with cisplatin and vindesine followed by UFT for completely resected pathologic stage IIIA-N2 non-small cell lung cancer: West Japan Study Group for Lung Cancer Surgery (WJSG), the 5th study. [abstract]. Proc Am Soc Clin Oncol 23 (2005) 7262
26. Hamada C., Tanaka F., Ohta M., et al. Meta-analysis of postoperative adjuvant chemotherapy with tegafur-uracil in non-small-cell lung cancer. J Clin Oncol 23 (2005) 4999-5006
27. Stewart L.A., Burdett S., Tierney J.F., et al. Surgery and adjuvant chemotherapy compared to surgery alone in non-small cell lung cancer: a meta-analysis using individual patient data from randomized clinical trials. [abstract]. Proc Am Soc Clin Oncol 25 (2007) 7552
28. PORT Meta-Analysis Trialists Group. Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials. Lancet 352 (1998) 257-263
29. Burdett S., Stewart L., and PORT Meta-analysis Group. Postoperative radiotherapy in non-small-cell lung cancer: update of an individual patient data meta-analysis. Lung Cancer 47 (2005) 81-83
30. Bonner J.A. The role of postoperative radiotherapy for patients with completely resected nonsmall cell lung carcinoma: seeking to optimize local control and survival while minimizing toxicity. Cancer 86 (1999) 195-196
31. Machtay M., Kaiser L.R., and Glatstein E. Reality and meta-analyses. Chest 118 (2000) 835-836
32. Marks L.B., and Prosnitz L.R. Postoperative radiotherapy for lung cancer: the breast cancer story all over again?. Int J Radiat Oncol Biol Phys 48 (2000) 625-627
33. Munro A.J. What now for postoperative radiotherapy for lung cancer?. Lancet 352 (1998) 250-251
34. Bogart J.A., and Aronowitz J.N. Localized non-small cell lung cancer: adjuvant radiotherapy in the era of effective systemic therapy. Clin Cancer Res 11 (2005) 5004S-5010S
35. Phlips P., Rocmans P., Vanderhoeft P., et al. Postoperative radiotherapy after pneumonectomy: impact of modern treatment facilities. Int J Radiat Oncol Biol Phys 27 (1993) 525-529
36. Roach III M., Gandara D.R., You H.S., et al. Radiation pneumonitis following combined modality therapy for lung cancer: analysis of prognostic factors. J Clin Oncol 13 (1995) 2606-2612
37. Lally B.E., Zelterman D., Colasanto J.M., et al. Postoperative radiotherapy for stage II or III non-small-cell lung cancer using the Surveillance, Epidemiology, and End Results database. J Clin Oncol 24 (2006) 2998-3006
38. Lally B.E., Detterbeck F.C., Geiger A.M., et al. The risk of death from heart disease in patients with nonsmall cell lung cancer who receive postoperative radiotherapy: analysis of the Surveillance, Epidemiology, and End Results database. Cancer 110 (2007) 911-917
39. Le Pechoux C., Dunant A., and Pignon J.-P. Need for a new trial to evaluate adjuvant postoperative radiotherapy in non-small-cell lung cancer patients with N2 mediastinal involvement. J Clin Oncol 25 (2007) e10-e11
40. Pisters K.M.W., Evans W.K., Azzoli C.G., et al. Cancer Care Ontario and American Society of Clinical Oncology adjuvant chemotherapy and adjuvant radiation therapy for stages I-IIIA resectable non-small-cell lung cancer guideline. J Clin Oncol 25 (2007) 5506-5518
41. Robinson L.A., Ruckdeschel J.C., Wagner Jr. H., et al. Treatment of non-small cell lung cancer, stage IIIA: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 132 (2007) S243-S265
42. Keller S.M., Adak S., Wagner H., et al. A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer. N Engl J Med 343 (2000) 1217-1222
43. Bradley J.D., Paulus R., Graham M.V., et al. Phase II trial of postoperative adjuvant paclitaxel/carboplatin and thoracic radiotherapy in resected stage II and IIIA non-small-cell lung cancer: promising long-term results of the Radiation Therapy Oncology Group-RTOG 9705. J Clin Oncol 23 (2005) 3480-3487
44. Greco F.A., Burris III H.A., Gray J.R., et al. Paclitaxel and carboplatin adjuvant therapy alone or with radiotherapy for resected nonsmall cell lung carcinoma: a feasibility study of the Minnie Pearl Cancer Research Network. Cancer 92 (2001) 2142-2147
45. Andre F., Grunenwald D., Pujol J.L., et al. Patterns of relapse of N2 nonsmall-cell lung carcinoma patients treated with preoperative chemotherapy: should prophylactic cranial irradiation be reconsidered?. Cancer 91 (2001) 2394-2400
46. Mamon H.J., Yeap B.Y., Janne P.A., et al. High risk of brain metastases in surgically staged IIIA non-small-cell lung cancer patients treated with surgery, chemotherapy, and radiation. J Clin Oncol 23 (2005) 1530-1537
47. Auperin A., Arriagada R., Pignon J.P., et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. N Engl J Med 341 (1999) 476-484
48. Slotman B., Faivre-Finn C., Kramer G., et al. Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med 357 (2007) 664-672
49. Available at:. www.rtog.org Accessed May 8, 2008
50. Pottgen C., Eberhardt W., Grannass A., et al. Prophylactic cranial irradiation in operable stage IIIA non-small-cell lung cancer treated with neoadjuvant chemoradiotherapy: results from a German multicenter randomized trial. J Clin Oncol 25 (2007) 4987-4992
51. Pepe C., Hasan B., Winton T.L., et al. Adjuvant vinorelbine and cisplatin in elderly patients: National Cancer Institute of Canada and Intergroup Study JBR.10. J Clin Oncol 25 (2007) 1553-1561
52. Roth J.A., Fossella F., Komaki R., et al. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small cell lung cancer. J Natl Cancer Inst 86 (1994) 673-680
53. Rosell R., Gomez-Codina J., Camps C., et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med 330 (1994) 153-158
54. Depierre A., Milleron B., Moro-Sibilot D., et al. Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIA non-small-cell lung cancer. J Clin Oncol 20 (2002) 247-253
55. Nagai K., Tsuchiya R., Mori T., et al. A randomized trial comparing induction chemotherapy followed by surgery with surgery alone for patients with stage IIIA N2 non-small cell lung cancer (JCOG 9209). J Thorac Cardiovasc Surg 125 (2003) 254-260
56. Gilligan D., Nicolson M., Smith I., et al. Preoperative chemotherapy in patients with resectable non-small cell lung cancer: results of the MRC LU22/NVALT 2/EORTC 08012 multicentre randomized trial and update of systematic review. Lancet 369 (2007) 1929-1937
57. Felip E., Rosell R., Massuti B., et al. The NATCH trial: observations on the neoadjuvant arm. [abstract]. Proc Am Soc Clin Oncol 25 (2007) 7578
58. Sandler A.B., Gray R., Perry M.C., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355 (2006) 2542-2550
59. Available at:. www.clinicaltrials.gov Accessed June 19, 2008
60. Sienel W., Verwerk C., Linder A., et al. Melanoma associated antigen (MAGE)-A3 expression in stages I and II non-small cell lung cancer: results of a multi-center study. Eur J Cardiothorac Surg 24 (2004) 131-134
61. Vansteenkiste J., Zielinski M., Dahabre J., et al. Multi-center, double-blind, randomized, placebo-controlled phase II study to assess the efficacy of recombinant MAGE-A3 vaccine as adjuvant therapy in stage IB/II MAGE-A3-positive, completely resected, non-small cell lung cancer. [abstract]. Proc Am Soc Clin Oncol 24 (2006) 7019
62. Lord R.V., Brabender J., Gandara D., et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 8 (2002) 2286-2291
63. Olaussen K.A., Dunant A., Fouret P., et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355 (2006) 983-991
64. Bepler G., Kusmartseva I., Sharma S., et al. RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer. J Clin Oncol 24 (2006) 4731-4737
65. Zheng Z., Chen T., Li X., et al. DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med 356 (2007) 800-808
66. Simon G.R., Williams C.C., Chiappori A.A., et al. Molecular analysis-directed individualized therapy (MADeIT) in advanced non-small cell lung cancer. [abstract]. Proc Am Soc Clin Oncol 25 (2007) 7502